Just as generic drugs have dramatically lowered the price of some common medicines and expanded access to them, so follow-on versions of complex biologic drugs to treat diseases like cancer and multiple sclerosis could benefit patients and reduce costs.
Novartis collaborates with others to help address some of the world’s greatest health challenges. Our corporate responsibility programs help more people secure the healthcare they need, regardless of where they live.
As the Ebola outbreak in West Africa continues to expand with isolated cases now being reported in Europe and North America, Novartis and its employees are contributing aid and pursuing research to help fight the deadly virus.
Interview with Mahesh P. Karande, Head of the Africa Cluster for Novartis. In this role, he is responsible for leading Novartis business activities in sub-Saharan Africa.
How Novartis is working towards the elimination of leprosy across the world with partners such as the World Health Organization (WHO) by donating multidrug therapy (MDT) to treat leprosy patients globally.
Novartis runs an annual program to support independent eye care initiatives worldwide via grant funding, including some in the world’s most remote areas and deprived communities.
Engineers spent two decades developing a new generation of contact lenses, Dailies Total1, to address the issue of discomfort users experience with existing silicone hydrogel lenses.
Efforts to improve health care in Africa take on many forms, the Novartis Institutes for BioMedical Research (NIBR) is contributing by discovering novel medicines that address patient needs.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.